Literature DB >> 24056291

Factors that influence the bleeding phenotype in severe hemophilic patients.

Pablo Rendo1, Frank Shafer, Joan M Korth-Bradley, Krupa Sivamurthy, Jorge Korin.   

Abstract

Hemophilia A and B are rare, X-linked bleeding disorders resulting from a partial or total deficiency of functionally active coagulation factor VIII or factor IX, respectively. Endogenous factor levels have traditionally been used to characterize the severity of the disorder, with severe hemophilia considered as circulating levels of factor less than 1% of normal. Identifying patients with severe hemophilia is essential to effective treatment, since these patients are at highest risk of spontaneous life or limb-threatening bleeding and disability resulting from repeated joint bleeding and are most likely to benefit from prophylaxis. However, there is variability in bleeding tendency, even among patients with severe hemophilia. This article will review potential modifiers of hemophilia-associated bleeding other than endogenous factor activity, which may influence bleeding tendencies and complications in hemophilic patients considered to have severe hemophilia. These potential modifiers include physiologic factors, such as elements of the hemostatic system; pathophysiologic factors, such as hemophilic arthropathy, associated inflammation, and angiogenesis; and others, such as seasonal variation, body weight, and physical activity.

Entities:  

Mesh:

Year:  2013        PMID: 24056291     DOI: 10.1097/MBC.0b013e3283614210

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  5 in total

Review 1.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

2.  Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.

Authors:  Anita Shah; Alexander Solms; Dirk Garmann; Yvonne Katterle; Verzhiniya Avramova; Stanislav Simeonov; Toshko Lissitchkov
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

3.  Evaluation of recombinant factor VIII Fc (Eloctate) activity by thromboelastometry in a multicenter phase 3 clinical trial and correlation with bleeding phenotype.

Authors:  Frank Driessler; Maricel G Miguelino; Glenn F Pierce; Robert T Peters; Jurg M Sommer
Journal:  Blood Coagul Fibrinolysis       Date:  2017-10       Impact factor: 1.276

4.  Diagnostic Values of Inflammatory and Angiogenic Factors for Acute Joint Bleeding in Patients With Severe Hemophilia A.

Authors:  Huijuan Xu; Ren Zhong; Kai Wang; Xuerong Li; Yanxia Zhao; Jian Jiang; Shaoyong Si; Lirong Sun
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

5.  PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.

Authors:  Elena Santagostino; Gili Kenet; Kathelijn Fischer; Tina Biss; Sanjay Ahuja; MacGregor Steele
Journal:  Haemophilia       Date:  2020-03-25       Impact factor: 4.287

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.